1307809-75-1

Upstream product

• 7063-99-2 ethyl 5-phenylisoxazole-3-carboxylate 
• 536-74-3 phenylacetylene 
• 3470-50-6 6-Hydroxy-1-tetralone 
• 1236188-85-4 ethyl 4-iodo-5-phenylisoxazole-3-carboxylate 
• 1236188-86-5 ethyl 5-phenyl-4-(trifluoromethyl)isoxazole-3-carboxylate 
• 1236188-87-6 5-phenyl-4-(trifluoromethyl)isoxazole-3-carboxylic acid 
• 1307812-49-2 3-(5-phenyl-4-(trifluoromethyl)isoxazol-3-yl)-7-vinyl-4,5-dihydronaphtho[1,2-c]isoxazole 
• 1307812-08-3 6-Vinyl-3,4-dihydronaphthalen-1(2H)-one 
• 1307812-05-0 6-vinyl-3,4-dihydronaphthalen-1(2H)-one oxime 
• 1307812-71-0 tert-butyl 6,8-dioxo-2,5,7-triazaspiro[3.4]octane-2-carboxylate 
• 1026796-27-9 2,5,7-triazaspiro[3.4]octane-6,8-dione hydrochloride 
• 1307812-51-6 7-(bromomethyl)-3-(5-phenyl-4-(trifluoromethyl)isoxazol-3-yl)-4,5-dihydronaphtho[1,2-c]isoxazole 
• 1307812-50-5 (3-(5-phenyl-4-(trifluoromethyl)isoxazol-3-yl)-4,5-dihydronaphtho[1,2-c]isoxazol-7-yl)methanol 

Relevant academic research and scientific papers

TRICYCLIC HETEROCYCLIC COMPOUNDS

Disclosed are compounds of Formula (I) or stereoisomers or salts thereof, wherein: X1, X2, X3, W, Q1, Q2, and G2 are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.